Evidence map›Paper›PMID 36351586›Full record

ReviewInternal medicine (Tokyo, Japan)2023

Kidney Podocyte Zebra Bodies after Lung Transplantation for Lymphangioleiomyomatosis.

Takashi Ishide, Hiroshi Nishi, Shinako Miyano, Yosuke Hirakawa, Kenjiro Honda, Hiroyuki Abe, Masaaki Sato, Masaomi Nangaku

Open access · diamondAbstract readCase ReportsReview
In one paragraph

Review in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Takashi IshideDivision of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Japan.
Hiroshi NishiDivision of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Japan.
Shinako MiyanoDivision of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Japan.
Yosuke HirakawaDivision of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Japan.
Kenjiro HondaDivision of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Japan.
Hiroyuki AbeDepartment of Pathology, The University of Tokyo Graduate School of Medicine, Japan.
Masaaki SatoDepartment of Thoracic Surgery, The University of Tokyo Graduate School of Medicine, Japan.
Masaomi NangakuDivision of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Japan.
The University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 55-year-old woman showed progressive renal dysfunction after unilateral deceased-donor lung transplantation for lymphangioleiomyomatosis. A kidney biopsy showed a striped pattern of interstitial fibrosis, suggesting calcineurin inhibitor toxicity, and zebra body accumulation predominantly in the podocytes, characteristics of Fabry disease. Nevertheless, she had no extra-renal symptoms of the disease, and gene testing identified no known pathogenic variant or exon deletion. Our case report and literature review suggest that this atypical lysosomal inclusion may be phospholipidosis induced by sertraline. Potential underlying etiologies linking zebra body deposits may be not only hereditary but also drug-induced phospholipidosis.

Indexed as

Fabry DiseaseLung TransplantationLymphangioleiomyomatosisPodocytesFemaleHumansKidneycalcineurin inhibitorchronic kidney diseasedrug-induced phospholipidosisfabry diseaselung transplantationzebra body

Identifiers

PMID36351586
PMCPMC10372279
OpenAlexW4308577338

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.